More recently, Tawbi and colleagues evaluated, in a phase II/III global randomized control trial, the impact of a combination of nivolumab and relatlimab, a lymphocyte activation gene 3 (LAG-3) inhibitor, in treatment-naïve metastatic or unresectable stage III melanoma as compared to nivolumab alone. Here, LAG3 is linked to melanoma.